Non-alcoholic fatty liver disease (NAFLD) has become one of the most common causes of
liver diseases globally, with a projected exponential rise. In contrast to the exponential rise …

Aim This systematic review and meta-analysis was conducted to evaluate the efficacy and
safety of 4 mg saroglitazar treatment in patients with non-alcoholic fatty liver disease …

Saroglitazar, a dual peroxisome proliferator activated receptor α/γ agonist, approved for
diabetic dyslipidemia (DD), is potential therapeutic option for non-alcoholic fatty liver …

Background & Aims Cardiovascular disease is the leading cause of mortality in nonalcoholic
fatty liver disease (NAFLD). The aim of this study was to evaluate the effects of saroglitazar …

Abstract Background and Aim Saroglitazar, a dual PPAR α/γ agonist, is useful in
management of NAFLD and diabetic dyslipidemia. Here, we report the safety and efficacy of …

Abstract Introduction: Non Alcoholic Fatty Liver Disease (NAFLD) is a commonly
encountered problem which affects one third of the general population. Saroglitazar, a …

Methods: Evidence on saroglitazar was sourced from PubMed database, google scholar,
and conference abstracts from inception to 31 st December 2022. This systematic review …

Objective To undertake a network meta-analysis to compare the relative efficacy of a dual
peroxisome proliferator-activated receptor (PPAR) α and PPARγ agonist, glucagon-like …

methods: This was an ongoing observationalstudy with the sample size of 52 patients
having Nonalcoholic fatty liver disease and dyslipidaemia with or withoutType 2 Diabetes …

Background Saroglitazar is a novel, dual peroxisome proliferator-activated receptors-α/γ
agonist and is being investigated for the treatment of nonalcoholic fatty liver disease …